UCB — Major Shareholding Notification 2017

Jan 16, 2017

Transparency notification

Brussels (Belgium), 16 January 2017 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 12 January 2017, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.).

BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and has crossed downward the 3% threshold.

On 11 January 2017, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 802 062 UCB shares with voting rights (versus 5 923 369 UCB shares in its previous notification dated 30 December 2016), representing 2.98% of the total number of shares issued by the company (194 505 658) (versus 3.05% in the notification dated 30 December 2016).

2. Content of the notification

The transparency notification dated 12 January 2017 includes the following information:

• Reason for the notification: Acquisition or disposal of voting securities or voting rights
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement:

Name	Address (for legal entities)
BlackRock, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG	Max-Joseph-Straße 6, Munich, 80333, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock International Limited	Exchange Place One, 1 Semple Street, Edinburgh, EH3 8BL, U.K.
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan

• Date on which the threshold is crossed: 11 January 2017.
• Threshold crossed (in %): 3%.
• Denominator: 194 505 658.
• Notified details:

UCB
News

A) Voting rights		Previous notification		After the transaction
		# of voting rights			# of voting rights			% of voting rights
Holders of voting rights					Linked to securities		Not linked to the securities	Linked to securities		Not linked to the securities
$\overline{0}$ BlackRock, Inc.				$\overline{0}$			0,00%
BlackRock (Netherlands) B.V.	19.816			19.816			0,01%
BlackRock (Singapore) Limited		7.217			6.386			0,00%
BlackRock Advisors (UK) Limited		1.001.729			890.924			0,46%
BlackRock Advisors, LLC		50.973			59.174			0,03%
BlackRock Asset Management Canada Limited	61.391				61.391			0,03%
BlackRock Asset Management Deutschland AG	225.537			230.706			0,12%
BlackRock Asset Management North Asia Limited	644			644		0,00%
BlackRock Financial Management, Inc.		79.725			79.725			0,04%
BlackRock Fund Advisors		1.767.774			1.779.299			0,91%
BlackRock Institutional Trust Company, National Association	2.024.454			2.038.642				1,05%
BlackRock International Limited	12.615			11.927			0.01%
(Australia) Limited	BlackRock Investment Management 41.852			41.852				0,02%
BlackRock Investment Management (UK) Limited		161.576		159.092					0,08%
BlackRock Investment Management, LLC		237.680		235.990				0,12%
BlackRock Japan Co., Ltd.		230.386			186.494		0,10%
Subtotal		5.923.369			5.802.062			2,98%
		TOTAL			5.802.062		$\mathbf 0$	2,98%		0,00%
B) Equivalent financial instruments					After the transaction
Holders of equivalent financial instruments		Type of financial instrument		Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised			% of voting rights	Settlement
BlackRock Advisors (UK) Limited		Securities Lent					162.356		0,08%	physical
BlackRock Fund Advisors		Securities Lent					1.118		0,00%	physical
BlackRock Institutional Trust Company, National Association		Securities Lent					9.606		0,00%	physical
BlackRock Japan Co., Ltd.		Securities Lent					7.625		0,00%	physical
BlackRock Institutional Trust Company, National Association		Contract for Difference					27.605		0,01%	cash

2.638

41.017

251.965

of voting rights

6.054.027

$0,00%$

$0,02%$

$0,13%$

% of voting rights

$3,11%$

cash

cash

	CALCULATE

Contract for Difference

Contract for Difference

TOTAL

TOTAL (A & B)

Company, National Association BlackRock International Limited

BlackRock Investment Management
(UK) Limited

• Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the PDF which is attached to the notification.

• Additional information:

The disclosure obligation arose due to voting rights for BlackRock, Inc. going below 3%.

3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following link.

Investor Relations

Antje Witte, Investor Relations, UCB T +32 2 559 94 14, antje.witte@ucb.com

Isabelle Ghellynck, Investor Relations, UCB T +32 2 559 95 88, isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news